← Browse by Condition
Medical Condition

neurodegenerative diseases

Total Trials
4
Recruiting Now
4
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for neurodegenerative diseases sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neurodegenerative diseases Clinical Trials

How many clinical trials are currently recruiting for neurodegenerative diseases?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for neurodegenerative diseases, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neurodegenerative diseases?
neurodegenerative diseases research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neurodegenerative diseases clinical trial?
Eligibility criteria for neurodegenerative diseases trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Epividian 1 trial
University of Exeter 1 trial
Kliniken Beelitz GmbH 1 trial
Ruijin Hospital 1 trial

Recruiting Clinical Trials

NCT03813862
Recruiting
Observational Pharmaco-Epidemiology Research & Analysis
Enrollment
2,000,000 pts
Location
United States
Sponsor
Epividian
View Trial →
NCT05518617
Recruiting
Molecular and Functional Imaging in Monogenic PD.
Enrollment
45 pts
Location
United Kingdom
Sponsor
University of Exeter
View Trial →
NCT04706234
Recruiting
Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases
Enrollment
350 pts
Location
Austria, Germany, Is...
Sponsor
Kliniken Beelitz GmbH
View Trial →
NCT05597410
Recruiting
Shanghai At Risk for Alzheimer's Disease: a Cohort Study
Enrollment
3,418 pts
Location
China
Sponsor
Ruijin Hospital
View Trial →

Related Conditions

parkinson disease (2) chronic disease (1) hiv aids (1) liver diseases (1) inflammatory bowel diseases (1) cardiovascular diseases (1) rheumatic diseases (1) nervous system disorder (1) neurodegenerative disease hereditary (1) parkinson s (1) multiple system atrophy (1) progressive supranuclear palsy (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology